A few days ago, Jiangsu Coast Pharmaceutical entered the administrative approval stage with the imitation of olanzapine tablets submitted for production in four categories. The total sales of this product in China's public medical institutions and Chinese urban physical pharmacies in 2019 exceeded 4 billion yuan, and it is also a Chinese urban entity. The best-selling neuroleptic at the pharmacy terminal.
Source: official website of the State Drug Administration
Olanzapine has an antagonistic effect on 5-HT, dopamine, and cholinergic. It is the first atypical antipsychotic approved for the long-term treatment of schizophrenia and the first SARS approved for the treatment of acute bipolar mania Type antipsychotic drugs have the advantages of rapid onset, fast sedation, fast dosage, and good safety and tolerability.
According to data from Mi Nei.com, olanzapine tablets have exceeded 4 billion yuan in terminal sales in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions), and physical pharmacies in cities in China in 2019. The terminal of public medical institutions in China is the "main battlefield" of olanzapine tablets, but this product is the best-selling neuroleptic at the terminal of physical pharmacies in cities in China.
Sales of Olanzapine Tablets in Entity Pharmacies in Chinese Cities
Source: Mi Nei.com, China's urban entity pharmacy terminal competition pattern
Affected by the epidemic and other factors, the sales of olanzapine tablets in physical pharmacies in Chinese cities are expected to decline in 2020, but in the competitive landscape of neuroleptic products, the product still leads with a 33% market share.
The market size of terminal neuroleptics in public medical institutions in China exceeds 10 billion yuan. In the product competition landscape, dexmedetomidine hydrochloride injection steadily ranks first. This product was included in the 4+7 centralized procurement in 2018. Evaluation’s advantages have been successfully won the bid, and the market share has soared from 0.22% in 2018 to 84.28% in the first half of 2020. With this product, in the competitive landscape of neuroleptic manufacturers in the first half of 2020, Yang Zijiang replaced Hausen to "dominate" the market...
Yangtze River's new class of neuroleptic drugs for production
Source: Meinenet MED2.0 Chinese Drug Evaluation Database
According to data from Minai.com, Yangtze River currently submits applications for the listing of 5 neuroleptic drugs under the new registration classification. Dexmedetomidine hydrochloride injection has been successfully approved for production and deemed to have been reviewed. Olanzapine tablets are expected to become the company's second product. A neuroleptic drug approved for marketing.
Source: Minei.com database, the official of the State Food and Drug Administration
Comments
Post a Comment